Currently, Cara Therapeutics Inc [CARA] is trading at $0.37, up 27.97%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CARA shares have gain 34.56% over the last week, with a monthly amount drifted -45.60%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Cara Therapeutics Inc [NASDAQ: CARA] stock has seen the most recent analyst activity on June 13, 2024, when Stifel downgraded its rating to a Hold and also revised its price target to $1 from $6. Previously, Needham downgraded its rating to Hold on June 13, 2024. On June 13, 2024, downgrade downgraded it’s rating to Neutral. Canaccord Genuity downgraded its rating to a Hold and decreased its price target to $1 on June 13, 2024. BofA Securities downgraded its rating to a Underperform and reduced its price target to $6 on March 08, 2023. JP Morgan upgraded its rating to Overweight for this stock on March 08, 2022, and upped its price target to $20.
This stock has fluctuated between a low of $0.24 and a high of $3.45 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $14.5 within the next 12 months. Cara Therapeutics Inc [NASDAQ: CARA] shares were valued at $0.37 at the most recent close of the market. An investor can expect a potential return of 3818.92% based on the average CARA price forecast.
Analyzing the CARA fundamentals
Trailing Twelve Months sales for Cara Therapeutics Inc [NASDAQ:CARA] were 16.94M which represents -65.37% decline. Gross Profit Margin for this corporation currently stands at 0.74% with Operating Profit Margin at -7.1%, Pretax Profit Margin comes in at -7.23%, and Net Profit Margin reading is -7.23%. To continue investigating profitability, this company’s Return on Assets is posted at -1.36, Equity is -1.74 and Total Capital is -1.6. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.3.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.3138 points at the first support level, and at 0.2616 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.4141, and for the 2nd resistance point, it is at 0.4622.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Cara Therapeutics Inc [NASDAQ:CARA] is 5.38. Further, the Quick Ratio stands at 5.20, while the Cash Ratio is 3.11. Considering the valuation of this stock, the price to sales ratio is 1.18, the price to book ratio is 0.67.
Transactions by insiders
Recent insider trading involved Posner Christopher, PRESIDENT AND CEO, that happened on May 02 ’24 when 3936.0 shares were sold. SEC’Y; CHIEF COMPLIANCE & G.C., Terrillion Scott completed a deal on Apr 05 ’24 to sell 2753.0 shares. Meanwhile, CHIEF MEDICAL OFFICER Goncalves Joana sold 2753.0 shares on Apr 05 ’24.
